CompletedPhase 1NCT05208814

A Study to Evaluate the Pharmacokinetics and Safety of TPN171H Tablets in Patients with Renal Insufficiency and Healthy Subjects

Studying Heritable pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vigonvita Life Sciences
Principal Investigator
Jia Miao
West China Hospital
Intervention
TPN171H single dose(drug)
Enrollment
16 enrolled
Eligibility
18-70 years · All sexes
Timeline
20222022

Study locations (2)

Collaborators

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05208814 on ClinicalTrials.gov

Other trials for Heritable pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Heritable pulmonary arterial hypertension

← Back to all trials